Back to Search
ERICA BRENDEL, MD
MD
Psychiatry Physician
NPI: 1861676801Individual
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
MD019381E(PA)
Research & Publications (17)
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
PMID 19101137·Eur J Cancer·2009
3-trial
Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
PMID 18343242·Clin Ther·2008
2-rct
Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: first-in-man study of BAY 63-9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties.
PMID 17899046·Eur J Clin Pharmacol·2007
2-rct
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
PMID 17363536·Clin Cancer Res·2007
3-trial
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
PMID 17095207·Eur J Cancer·2007
3-trial
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
PMID 16500908·Ann Oncol·2006
3-trial
Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.
PMID 16425970·Int J Clin Pharmacol Ther·2006
4-observational
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
PMID 16197622·Clin Colorectal Cancer·2005
3-trial
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
PMID 15870716·Br J Cancer·2005
3-trial
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
PMID 15613696·J Clin Oncol·2005
3-trial
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
PMID 15598035·Int J Clin Pharmacol Ther·2004
3-trial
Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry.
PMID 15329840·J Mass Spectrom·2004
4-observational
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
PMID 15277271·Ann Oncol·2004
3-trial
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
PMID 14692719·Int J Clin Pharmacol Ther·2003
3-trial
The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
PMID 12047482·Br J Clin Pharmacol·2002
3-trial
Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast.
PMID 12012144·Eur J Clin Pharmacol·2002
3-trial
Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union.
PMID 11923060·Eur J Pharm Sci·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 111 N 49TH ST
PHILADELPHIA, PA 19139 - Phone
- (215) 471-1576
Quick Facts
- NPI
- 1861676801
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 17
Are you this provider?
Claim Your Profile